Catalyst Wire Dossier Catalyst Wire Dossier

Otarmeni

lunsotogene parvec-cwha
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Otarmeni. Get the full timeline:

Most recent: FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

See pricing